Mast-cell stabilization to decrease neurofibroma growth: preliminary experience with ketotifen
VM Riccardi - Archives of dermatology, 1987 - jamanetwork.com
• Based on (1) the large numbers of mast cells present in neurofibromas,(2) the possibility
that these mast cells contribute directly to neurofibroma growth, and (3) the ability of ketotifen
therapy to stabilize (ie, block) mast-cell secretion, treatment with ketotifen was started in a
patient with severe neurofibromatosis (NF) in August 1983. Subsequently, ten additional
patients with one or more symptomatic neurofibromas were treated with comparable doses
of ketotifen, 2 to 4 mg/d, orally administered for 30 to 43 months. This represents a total of …
that these mast cells contribute directly to neurofibroma growth, and (3) the ability of ketotifen
therapy to stabilize (ie, block) mast-cell secretion, treatment with ketotifen was started in a
patient with severe neurofibromatosis (NF) in August 1983. Subsequently, ten additional
patients with one or more symptomatic neurofibromas were treated with comparable doses
of ketotifen, 2 to 4 mg/d, orally administered for 30 to 43 months. This represents a total of …